We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2007 by Aalborg Universitetshospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00451984
First Posted: March 26, 2007
Last Update Posted: November 1, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Aalborg Universitetshospital
March 23, 2007
March 26, 2007
November 1, 2007
March 2007
Not Provided
Antibody response to hepatitis A and hepatitis B
Same as current
Complete list of historical versions of study NCT00451984 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2
Not Provided
The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
  • HIV Infections
  • Hepatitis A
  • Hepatitis B
  • Biological: Twinrix
  • Biological: interleukin-2
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
80
Not Provided
Not Provided

Inclusion Criteria:

  • Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion Criteria:

  • Prior hepatitis A or B
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
 
NCT00451984
VN2005/32
No
Not Provided
Not Provided
Not Provided
Aalborg Universitetshospital
Not Provided
Study Chair: Henrik Nielsen, MD, DMSci Aalborg Hospital, DK-9000 Aalborg, Denmark
Aalborg Universitetshospital
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top